Elizabeth Rhee on Muck Rack

Elizabeth Rhee

Get in touch with Elizabeth

Contact Elizabeth, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Erratum for Rhee et al., “Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants”

|
By Elizabeth Rhee, Matthew L. Rizk, Nicole Calder, Marcela Nefliu
| asm.org
ERRATUM Volume 62, no. 9, e00280-18, 2018, https://doi.org/10.1128/AAC.00280-18. The Acknowledgments section was incomplete and should appear as shown below. At the time the study was conducted, E.G.R., M.L.R., N.C., M.N., M.S.S., E.M., K.B., P.B., F.C.-G., P.J., Y.L., and J.R.B. were employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD), and they may own stock and/or stock options in the company.
Open in Who Shared Issue with article?

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

|
By Elizabeth Rhee, Matthew L. Rizk, Nicole Calder, Marcela Nefliu
| American Society for Microbiology (ASM)
ABSTRACTRelebactam is a novel class A and C β-lactamase inhibitor that is being developed in combination with imipenem-cilastatin for the treatment of serious infections with Gram-negative bacteria.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified